Gary Herman

Senior Vice President, Clinical Development Unit Head, Genetic Medicines · Regeneron Pharmaceuticals

Biopharmaceuticals

Gary Herman is senior vice president and clinical development unit head for genetic medicines at Regeneron Pharmaceuticals. He joined in 2015 after leading early-stage development at Merck and earlier academic medicine at the University of California, San Francisco.

Last reviewed: Oct 21, 2026

Gary Herman

Senior Vice President, Clinical Development Unit Head, Genetic Medicines Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Gary Herman is senior vice president and clinical development unit head for genetic medicines at Regeneron Pharmaceuticals. He joined in 2015 after leading early-stage development at Merck and earlier academic medicine at the University of California, San Francisco.

Career Highlights

  • Joined Regeneron in 2015.
  • Previously served as vice president and head of early-stage development at Merck.
  • Served on the Biomarkers Consortium executive committee from 2008 to 2015.

Professional Journey

Herman completed residency and postdoctoral training at the University of California, San Francisco and became an assistant professor there before entering the pharmaceutical industry.

At Merck, he held positions of increasing responsibility, ultimately becoming vice president and head of Early-Stage Development. From 2008 to 2015, he also served on the executive committee of the Biomarkers Consortium, a Foundation for the National Institutes of Health program.

He joined Regeneron in 2015 and now serves as senior vice president and clinical development unit head for Genetic Medicines. His background combines academic clinical training, early development leadership and collaboration on biomarkers with his current genetic medicines remit.

Education

Herman earned a BS in biochemistry and cell biology from the University of California, San Diego and an MD from Harvard Medical School.